Why Former a16z Partner Vijay Pande Is Choosing Concentrated AI Biotech Bets at VZVC

Former Andreessen Horowitz general partner Vijay Pande has shifted from managing billions in venture capital to running a boutique investment firm built around a small number of high-conviction healthcare investments and artificial intelligence-driven operations.

What Happened

Vijay Pande, a former Stanford University chemistry professor who previously built the distributed-computing initiative Folding@home, led healthcare and life sciences investments at Andreessen Horowitz (a16z) for more than a decade. During his tenure, the practice expanded to manage nearly $4 billion. In June of last year, Pande departed the venture giant to launch VZVC alongside longtime investor Zach Werner.

Unlike traditional venture firms that spread capital across dozens of portfolio companies annually, VZVC plans to make approximately five investments per year. On the investment side, the firm operates with only Pande and Werner. Rather than hiring associates, the firm relies on internally deployed AI agents to handle routine daily operations.

Key Highlights

• Concentrated portfolio: VZVC targets roughly five investments per year instead of the 30 or more deals typical of large venture funds.
• AI-assisted operations: The firm bypassed hiring investment associates after deploying AI agents to support day-to-day workflow.
• Focus areas: Pande is concentrating primary investment efforts on artificial intelligence for healthcare delivery and AI applications for clinical trials.
• High clinical failure rates: Pande pointed out that only 20 percent of drug candidates succeed from Phase 1 through Phase 3 trials, primarily because animal models fail to accurately predict human outcomes.
• Data challenges in biology: Unlike text-based machine learning, biological information cannot simply be gathered off the public internet, requiring specialized datasets and emerging biological foundation models.

Why This Matters

Drug development remains extremely costly, with failed clinical trials driving up the amortized expenses of new treatments. Pande explained that eight out of ten experimental drugs fail during human trials, often because foundational research relies heavily on animal models like mice that do not reliably mimic human biology. By using machine learning models that outperform traditional animal testing, developers aim to improve trial success rates and streamline costs.

Additionally, biological data cannot simply be scraped from web pages like language models scrape text. This constraint leads biotech enterprises to build isolated data silos. Pande noted that while founders protect proprietary assets, the field is beginning to see foundational biological models and atlases emerge, mirroring the rise of open-source models in standard computing.

What to Watch Next

In his current deployment strategy, Pande highlighted two key subsectors: AI applied to healthcare delivery and AI tools designed for clinical trials. On the corporate development front, Pande emphasized that technical founders must prioritize go-to-market execution, which he identified as being at least as challenging as developing underlying scientific technology.

Frequently Asked Questions

What is VZVC?

VZVC is an early-stage investment firm co-founded by Vijay Pande and Zach Werner, focusing on a small number of concentrated investments in artificial intelligence and healthcare.

Why did VZVC decide not to hire investment associates?

According to Pande, the firm initially considered hiring associates but found that AI agents developed within the firm were sufficient to manage day-to-day operations.

Why do most clinical drug trials fail?

Pande noted that approximately 80 percent of drug trials fail, largely because initial experiments rely on animal models that often do not translate accurately to human biology.

Source: TechCrunch interview with Vijay Pande.